Work

A call for global harmonization of phase I oncology trials: Results from two parallel, first-in-human phase I studies of DS-7423, an oral PI3K/mTOR dual inhibitor in advanced solid tumors conducted in the United States and Japan.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.2536

Authors: Tomoya Yokota, Johanna C. Bendell, Patricia LoRusso, Takahiro Tsushima, Ved Desai, Hirotsugu Kenmotsu, Junichiro Watanabe, Akira Ono, Bhavani G. Murugesan, Joseph Silva, Tateaki Naito, Jonathan Greenberg, Prasanna Kumar, Yibin Wang, Takahiro Jikoh, Ryota Shiga, Alan Loh Ho, Mrinal M. Gounder

Institutions: Shizuoka Cancer Center, Tennessee Oncology, Yale University, Stony Brook University Hospital, Memorial Sloan Kettering Cancer Center, Daiichi-Sankyo (Japan)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2651973063

Cites:

Cited by: 6

Related to: 10